Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models

Journal of Rheumatology

Volumn 32, Issue 3, 2005, Pages 469-476

  Baharav, Ehud ^a,b   Bar Yehuda, Sara ^a,b   Madi, Lea ^a   Silberman, Daniel ^a   Rath Wolfson, Lea ^b,c   Halpren, Marisa ^b,c   Ochaion, Avivit ^d   Weinberger, Abraham ^b   Fishman, Pnina ^a,b  

^a Can Fite BioPharma Ltd   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RABIN MEDICAL CENTER   (Israel)

^d Rabin Medical Center ^*

Author keywords

A3 Adenosine receptor agonist; Adjuvant arthritis; CF101; Collagen induced arthritis; Tropomyosin induced arthritis; Tumor necrosis factor

Indexed keywords

1 DEOXY 1 [6 [[(3 IODOPHENYL)METHYL]AMINO] 9H PURIN 9 YL] N METHYL DEXTRO RIBOFURANURONAMIDE; 2 CHLORO N 6 (3 IODOBENZYL)ADENOSINE 5' N METHYLURONAMIDE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; ADENOSINE A3 RECEPTOR AGONIST; ADJUVANT; COLLAGEN; METHOTREXATE; TROPOMYOSIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADJUVANT ARTHRITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; BODY WEIGHT; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG SCREENING; EXPERIMENTAL MODEL; EXTRACT; FEMALE; HISTOPATHOLOGY; LOW DRUG DOSE; LYMPH NODE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPLEEN; SPLEEN CELL; SYNOVIUM; WESTERN BLOTTING;

ADENOSINE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; COLLAGEN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; JOINTS; LYMPH NODES; MALE; MICE; MICE, INBRED DBA; QUINAZOLINES; RATS; RECEPTOR, ADENOSINE A3; SPLEEN; TRIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 15044343787     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Cvetkovic JT, Wallberg-Jonsson S, Stegmayr B, Rantapaa-Dahlqvist S, Lefvert AK. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-α, IL-1β, and IL-1Ra genes. J Rheumatol 2002;29:212-9.
2. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human TNF: a predictive genetic model of arthritis. EMBO J 1991;10:4025-31.
3. Taylor PC. Anti-TNF therapy for rheumatoid arthritis and other inflammatory diseases. Mol Biotechnol 2001;19:153-68.
4. Feldmann M, Andreakos E, Smith C, et al. Is NF-κB a useful therapeutic target in rheumatoid arthritis? Ann Rheum Dis 2002;61 Suppl:1113-8.
5. Ohana G, Bar-Yehuda S, Barer F, Fishman P. Differential effect of adenosine on tumor and normal cell growth: focus on the A3 adenosine receptor. J Cell Physiol 2001;186:19-23.
6. Virag L, Szabo C. Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death. FASEB J 2001;15:99-107.
7. Palmer TM, Stiles GL. Adenosine receptors. Neuropharmacology 1995;34:683-94.
8. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, Jacobson MA. Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 2000;275:4429-34.
9. Ohta S, Harigai M, Tanaka M, et al. Tumor necrosis factor-α (TNF-α) converting enzyme contributes to production of TNF-α in synovial tissues from patients with rheumatoid arthritis. J Rheumatol 2001;28:1756-63.
10. Ohta A, Sitkovsky M. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001;414:916-20.
11. Khoa ND, Montesinos MC, Reiss AB, Delano D, Awadallah N, Cronstein BN. Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. J Immunol 2001;167:4026-32.
12. Baharav E, Dubrosin A, Fishman P, Bar-Yehuda S, Halpren M, Weinberger A. Suppression of experimental zymosan induced arthritis by adenosine. Drug Dev Res 2003;57:182-6.
13. Montesinos MC, Yap JS, Desi A, Posadas I, McCary CT, Cronstein BN. Reversal of the antiinflammatory effect of methotrexate by the selective adenosine receptor antagonists theophylline and caffeine. Arthritis Rheum 2000;43:656-63.
14. McWhinney CD, Dudley MW, Bowlin TL, et al. Activation of adenosine A3 receptors on macrophages inhibits tumor necrosis factor-α. Eur J Pharmacol 1996;310:209-16.
15. Hasko G, Nemeth ZH, Vizi ES, Salzman AL, Szabo C. An agonist of adenosine A3 receptors decreases interleukin-12 and interferon-γ production and prevents lethality in endotoxemic mice. Eur J Pharmacol 1998;358:261-8.
16. Mor F, Weinberger A, Cohen IR. Identification of α-tropomyosin as a target self-antigen in Behcet's syndrome. Eur J Immunol 2002;32:356-65.
17. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, editors. Adjuvant arthritis in the rat. Current protocols in immunology. Philadelphia: John Wiley & Sons; 1996:15.4.
18. Goldenberg DL, Chisholm PL, Rice PA. Experimental models of bacterial arthritis: a microbiologic and histopathologic characterization of the arthritis after the intraarticular injections of Neisseria gonorrhoeae, Staphylococcus aureus, group A streptococci, and Escherichia coli. J Rheumatol 1983;1:5-11.
19. Stanescu R, Lider O, van Eden W, Holoshitz J, Cohen IR. Histopathology of arthritis induced in rats by active immunization to mycobacterial antigens or by systemic transfer of T lymphocyte lines. A light and electron microscopic study of the articular surface using cationized ferritin. Arthritis Rheum 1987;30:779-92.
20. Fishman P, Bar-Yehuda S, Barer F, Madi L, Multani AF, Pathak S. The A3 adenosine receptor as a new target for cancer therapy and chemoprotection. Exp Cell Res 2001;269:230-6.
21. Madi L, Bar-Yehuda S, Barer F, Ardon E, Ochaion A, Fishman P. A3 adenosine receptor activation in melanoma cells: association between receptor fate and tumor growth inhibition. J Biol Chem 2003;278:42121-30.
22. Ohana G, Bar-Yehuda S, Arich A, et al. Inhibition of primary colon carcinoma growth and liver metastasis by the A3 adenosine receptor agonist CF101. Br J Cancer 2003;89:1552-8.
23. Montesinos MC, Desai A, Delano D, et al. Adenosine A2A or A3 receptors are required for inhibition of inflammation by methotrexate and its analog MX-68. Arthritis Rheum 2003;48:240-7.
24. Szabo C, Scott GS, Virag L, et al. Suppression of macrophage inflammatory protein (MIP)-1α production and collagen-induced arthritis by adenosine receptor agonists. Br J Pharmacol 1998;125:379-87.
25. Grossman JM, Brahn E. Rheumatoid arthritis: current clinical and research directions. J Womens Health 1997;6:627-38.
26. Fabris M, Tolusso B, Di Poi E, Assaloni R, Sinigaglia L, Ferraccioli G. Tumor necrosis factor-α receptor II polymorphism in patients from southern Europe with mild-moderate and severe rheumatoid arthritis. J Rheumatol 2002;29:1847-50.
27. Goldring SR. Bone and joint destruction in rheumatoid arthritis: what is really happening? J Rheumatol 2002;29 Suppl 65:44-8.
28. Muller-Ladner U, Gay RE, Gay S. Role of nuclear factor κB in synovial inflammation. Curr Rheumatol Rep 2002;4:201-7.
29. Youn J, Kim HY, Park JH, et al. Regulation of TNF-α-mediated hyperplasia through TNF receptors, TRAFs, and NF-κB in synoviocytes obtained from patients with rheumatoid arthritis. Immunol Lett 2002;83:85-93.
30. Liu J, Beller D. Aberrant production of IL-12 by macrophages from several autoimmune-prone mouse strains is characterized by intrinsic and unique patterns of NF-κ expression and binding to the IL-12 p40 promoter. J Immunol 2002;169:581-6.
31. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS. Inhibition of TNF-α expression by adenosine: role of A3 adenosine receptors. J Immunol 1996;156:3435-42.
32. Hasko G, Szabo C, Nemeth ZH, Kvetan V, McCarty Pastores S, Vizi ES. Adenosine receptor agonists differentially regulate IL-10, TNF-α, and nitric oxid production in RAW 264.7 macrophages and in endotoxemic mice. J Immunol 1996;157:4634-40.
33. Bowlin TL, Borcherding DR, Edwards CK 3rd, McWhinney CD. Adenosine A3 receptor agonists inhibit murine macrophage tumor necrosis factor-alpha production in vitro and in vivo. Int J Cancer 2002;99:386-95.
34. Aletaha D, Smolen JS. The rheumatoid arthritis patient in the clinic: comparing more than 1300 consecutive DMARD courses. Rheumatology Oxford 2002;41:1367-74.
35. Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002;4:266-73.
36. Allegra CJ, Drake JC, Jolivet J, Chabner BA. Inhibition of phosphoribosyl amino imidazole carboxamide transformylase by methotrexate and dehydrofolic acid polyglutamates. Proc Natl Acad Sci USA 1985;82:4881-5.
37. Weinblatt ME. Methotrexate in rheumatoid arthritis: toxicity issues. Br J Rheumatol 1996;35:403-5.
38. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
39. Goldbach-Mansky R, Lipsky PE. New concepts in the treatment of rheumatoid arthritis. Annu Rev Med 2003;54:197-216.
40. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
41. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:614-24.
42. Weisman MH. What are the risks of biologic therapy in rheumatoid arthritis? An update on safety. J Rheumatol 2002;65:33-8.
43. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002;46:2565-70.
44. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. J Am Acad Dermatol 2001;45:953-6.
45. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002;46:3151-8.